Mechanisms of inflammatory memory in the human respiratory mucosa

人体呼吸道粘膜炎症记忆机制

基本信息

  • 批准号:
    MR/Y000935/1
  • 负责人:
  • 金额:
    $ 216.95万
  • 依托单位:
  • 依托单位国家:
    英国
  • 项目类别:
    Fellowship
  • 财政年份:
    2023
  • 资助国家:
    英国
  • 起止时间:
    2023 至 无数据
  • 项目状态:
    未结题

项目摘要

Our lungs are regularly exposed to germs and pollutants, so the lining of the lungs acts as a physical and immune barrier against inhaled threats. The first line of defence is the "innate" immune system which has recently been shown to be able to "remember" past inflammatory events. Proteins involved in inflammation are created from instructions encoded within genes. Environmental exposures can alter the way our genes work by leaving an imprint (or "epigenetic" changes) which plays a key role in inflammatory memory. Although genetic information cannot be altered after it has been inherited, epigenetic changes can potentially be modified to regulate future responses. Inflammatory memory has been studied in blood but its role in human lungs is not well understood.Inflammatory memory may be especially important in conditions such as asthma which contributes to 455,000 deaths globally and UK healthcare costs of £3 billion annually. Common triggers for asthma attacks include viruses and air pollutants which cause serious airway inflammation. Treatment for asthma attacks has not changed in decades and requires steroids to reduce inflammation which has significant side effects. New approaches to treatment are urgently required, and the reversible nature of epigenetic changes makes them attractive targets. My preliminary research suggests that epigenetic modification may be used to reduce airway inflammation.The most relevant and direct way to study inflammation of the airways is by studying people. I carefully exposed volunteers to substances that cause short-term and limited inflammation using a nasal spray containing a pure synthetic compound (R848) to mimic a viral infection, safely recreating real-life scenarios in a controlled manner. I discovered that individuals with asthma experience faster and increased nasal inflammation compared to people without asthma. This suggests their cells are more likely to respond to external triggers resulting in excessive inflammation.The aim of this proposal is to find out whether people with asthma have epigenetic changes in their lungs before and after controlled exposure to R848 and air pollution. The project asks the following questions:1. Do cells in the lungs of people with asthma respond differently to a substance that mimics viruses from those without asthma?2. Do different inflammatory triggers (e.g., viruses and air pollution) cause epigenetic changes in the lungs and does this alter how the lungs work?3. Can we use drugs to target epigenetic changes and modify inflammatory responses?The research will take place with expert scientific partners in the University of Cambridge and in Vancouver, Canada. I will use cutting-edge molecular biology tools to study how the lungs respond to R848 and compare differences in people with and without asthma. I will examine whether cells from people with asthma have epigenetic changes that make them more prone to inflammation and whether this persists after inflammation. Air pollution is a key trigger for lung inflammation and collaborators in Vancouver have developed a controlled diesel exhaust exposure model which is safely tolerated in volunteers including those with asthma. I will use this model to study epigenetic and immune changes in the lungs in response to pollution. Finally, in order to help translate these research findings into potential new therapies, I will assess whether we can target these epigenetic changes to reduce airway inflammation in the lab.The results of the study will lead to the development of a unique approach to studying human lung inflammation that mimics viral infection, which can also be used in future to develop drugs that target inflammation. It will provide a detailed understanding of why people with asthma have excessive lung inflammation, and information on whether epigenetic changes can be modified by targeted drugs, which if successful could be translated into clinical trials.
我们的肺经常暴露在细菌和污染物中,所以肺的内壁就像一个物理和免疫屏障,可以抵御吸入的威胁。第一道防线是“先天”免疫系统,它最近被证明能够“记住”过去的炎症事件。与炎症有关的蛋白质是由基因编码的指令产生的。环境暴露可以通过留下印记(或“表观遗传”变化)来改变我们基因的工作方式,这在炎症记忆中起着关键作用。虽然遗传信息在遗传后不能改变,但表观遗传变化可能被修改以调节未来的反应。人们已经研究了血液中的炎症记忆,但它在人体肺部的作用还不清楚。炎症记忆在哮喘等疾病中可能尤为重要,哮喘导致全球45.5万人死亡,英国每年的医疗费用为30亿英镑。哮喘发作的常见诱因包括病毒和空气污染物,它们会导致严重的气道炎症。几十年来,哮喘发作的治疗方法没有改变,需要类固醇来减少炎症,而炎症有明显的副作用。迫切需要新的治疗方法,而表观遗传变化的可逆性使它们成为有吸引力的目标。我的初步研究表明,表观遗传修饰可能用于减少气道炎症。研究呼吸道炎症最相关和最直接的方法是对人进行研究。我小心翼翼地将志愿者暴露在会引起短期有限炎症的物质中,使用含有纯合成化合物(R848)的鼻腔喷雾剂来模拟病毒感染,以一种可控的方式安全地重现现实生活中的场景。我发现,与没有哮喘的人相比,患有哮喘的人鼻部炎症更快、更严重。这表明他们的细胞更有可能对导致过度炎症的外部诱因做出反应。这项提议的目的是找出哮喘患者在控制暴露于R848和空气污染之前和之后,肺部是否有表观遗传变化。该项目提出以下问题:1。哮喘患者肺部的细胞对一种模拟病毒的物质的反应与非哮喘患者不同吗?不同的炎症触发因素(如病毒和空气污染)是否会导致肺部的表观遗传变化,这是否会改变肺部的工作方式?我们可以用药物来靶向表观遗传变化和改变炎症反应吗?这项研究将与剑桥大学和加拿大温哥华的专家科学合作伙伴一起进行。我将使用尖端的分子生物学工具来研究肺部对R848的反应,并比较哮喘患者和非哮喘患者的差异。我将检查哮喘患者的细胞是否有使其更容易发生炎症的表观遗传变化,以及炎症后这种变化是否会持续。空气污染是引发肺部炎症的关键因素,温哥华的合作者开发了一种可控的柴油废气暴露模型,该模型在包括哮喘患者在内的志愿者中是安全耐受的。我将使用这个模型来研究肺部对污染的表观遗传和免疫变化。最后,为了帮助将这些研究结果转化为潜在的新疗法,我将评估我们是否可以在实验室中针对这些表观遗传变化来减少气道炎症。这项研究的结果将导致开发一种独特的方法来研究模拟病毒感染的人类肺部炎症,这也可以在未来用于开发针对炎症的药物。它将提供一个详细的了解为什么哮喘患者有过度的肺部炎症,以及是否可以通过靶向药物修改表观遗传变化的信息,如果成功,可以转化为临床试验。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Obesity dysregulates the pulmonary antiviral immune response.
  • DOI:
    10.1038/s41467-023-42432-x
  • 发表时间:
    2023-10-19
  • 期刊:
  • 影响因子:
    16.6
  • 作者:
    Almond, Mark;Farne, Hugo A.;Jackson, Millie M.;Jha, Akhilesh;Katsoulis, Orestis;Pitts, Oliver;Tunstall, Tanushree;Regis, Eteri;Dunning, Jake;Byrne, Adam J.;Mallia, Patrick;Kon, Onn Min;Saunders, Ken A.;Simpson, Karen D.;Snelgrove, Robert J.;Openshaw, Peter J. M.;Edwards, Michael R.;Barclay, Wendy S.;Heaney, Liam M.;Johnston, Sebastian L.;Singanayagam, Aran
  • 通讯作者:
    Singanayagam, Aran
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Akhilesh Jha其他文献

Early Career Members at the Lung Science Conference and the Sleep and Breathing Conference 2019
2019 年肺科学会议和睡眠与呼吸会议的早期职业成员
  • DOI:
    10.1183/20734735.0203-2019
  • 发表时间:
    2019
  • 期刊:
  • 影响因子:
    2
  • 作者:
    I. Almendros;N. El;Akhilesh Jha;Holly R. Keir;D. Lykouras;I. Mahmutovic Persson;N. Ubags;S. Bartel
  • 通讯作者:
    S. Bartel
Review of the British Thoracic Society Winter Meeting 2021, 24–26 November 2021
英国胸科学会 2021 年冬季会议回顾,2021 年 11 月 24-26 日
  • DOI:
  • 发表时间:
    2022
  • 期刊:
  • 影响因子:
    10
  • 作者:
    Akhilesh Jha;T. Ward;S. Walker;A. Goodwin;J. Chalmers
  • 通讯作者:
    J. Chalmers
Asthma: From Diagnosis to Endotype to Treatment.
哮喘:从诊断到内型再到治疗。
Topical TMPRSS2 inhibition prevents SARS-CoV-2 infection in differentiated primary human airway cells
局部 TMPRSS2 抑制可预防分化的原代人气道细胞中的 SARS-CoV-2 感染
  • DOI:
    10.1101/2021.04.23.440619
  • 发表时间:
    2021
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Wenrui Guo;Linsey M Porter;T. Crozier;M. Coates;Akhilesh Jha;M. Mckie;J. Nathan;P. Lehner;Edward J. D. Greenwood;F. McCaughan
  • 通讯作者:
    F. McCaughan
5. Respiratory Syncytial Virus
5.呼吸道合胞病毒
  • DOI:
  • 发表时间:
    2018
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Akhilesh Jha;Hannah Jarvis;Clementine S Fraser;P. Openshaw
  • 通讯作者:
    P. Openshaw

Akhilesh Jha的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似国自然基金

RIPK3蛋白及其RHIM结构域在脓毒症早期炎症反应和脏器损伤中的作用和机制研究
  • 批准号:
    82372167
  • 批准年份:
    2023
  • 资助金额:
    48.00 万元
  • 项目类别:
    面上项目
肠道菌群介导的脱氧胆酸激活S1PR2/NLRP3/IL-1β通路在炎症性肠病合并艰难梭菌感染中的致病机制研究
  • 批准号:
    82372306
  • 批准年份:
    2023
  • 资助金额:
    48.00 万元
  • 项目类别:
    面上项目
YTHDF1通过m6A修饰调控耳蜗毛细胞炎症反应在老年性聋中的作用机制研究
  • 批准号:
    82371140
  • 批准年份:
    2023
  • 资助金额:
    49.00 万元
  • 项目类别:
    面上项目
多孔Ti-MSNs@MGF+DX抗炎—成肌体系应用于颞下颌关节假体的作用和机制研究
  • 批准号:
    82370984
  • 批准年份:
    2023
  • 资助金额:
    48.00 万元
  • 项目类别:
    面上项目
上皮祖细胞应答巨噬细胞分泌因子IL-1β参与炎症微环境下输卵管纤毛分化障碍的机制研究
  • 批准号:
    82371691
  • 批准年份:
    2023
  • 资助金额:
    49.00 万元
  • 项目类别:
    面上项目
基于仿生矿化法构建氢离子捕获的炎症调节性水凝胶微球在卒中治疗中的研究
  • 批准号:
    82372120
  • 批准年份:
    2023
  • 资助金额:
    49.00 万元
  • 项目类别:
    面上项目
Caspase8和RIP3调控细胞程序性坏死的关键机制研究
  • 批准号:
    31970688
  • 批准年份:
    2019
  • 资助金额:
    58.0 万元
  • 项目类别:
    面上项目
炎症因子调控干眼病眼表黏蛋白表达的分子机制
  • 批准号:
    81100636
  • 批准年份:
    2011
  • 资助金额:
    23.0 万元
  • 项目类别:
    青年科学基金项目
TRAM基因选择性调控LPS失控性炎症反应的实验研究
  • 批准号:
    81071588
  • 批准年份:
    2010
  • 资助金额:
    33.0 万元
  • 项目类别:
    面上项目

相似海外基金

Metabolic mechanisms of cognitive decline in aging and AD mediated by inflammatory PGE2 signaling
炎症 PGE2 信号介导的衰老和 AD 认知能力下降的代谢机制
  • 批准号:
    10590390
  • 财政年份:
    2023
  • 资助金额:
    $ 216.95万
  • 项目类别:
Mechanisms underlying Sex differences in Cerebral Amyloid Angiopathy: The Fibrin-Microglia Crosstalk
脑淀粉样血管病性别差异的潜在机制:纤维蛋白-小胶质细胞串扰
  • 批准号:
    10662862
  • 财政年份:
    2023
  • 资助金额:
    $ 216.95万
  • 项目类别:
Mechanisms of protective memory CD8 T-cell induction by mRNA-LNP vaccines
mRNA-LNP 疫苗诱导保护性记忆 CD8 T 细胞的机制
  • 批准号:
    10753981
  • 财政年份:
    2023
  • 资助金额:
    $ 216.95万
  • 项目类别:
Mechanisms of cognitive control impairment in ME/CFS and PASC-ME/CFS
ME/CFS 和 PASC-ME/CFS 认知控制障碍的机制
  • 批准号:
    10717201
  • 财政年份:
    2023
  • 资助金额:
    $ 216.95万
  • 项目类别:
MultiOMICS to uncover immune and virological mechanisms that drive HIV DNA decay, restore immune homeostasis, and promote HIV specific immunity in PWH receiving cell therapies.
MultiOMICS 旨在揭示驱动 HIV DNA 衰变的免疫和病毒学机制,恢复免疫稳态,并促进接受细胞疗法的感染者的 HIV 特异性免疫。
  • 批准号:
    10731666
  • 财政年份:
    2023
  • 资助金额:
    $ 216.95万
  • 项目类别:
Dopaminergic mechanisms of resilience to Alzheimer's disease neuropathology
阿尔茨海默病神经病理学恢复的多巴胺能机制
  • 批准号:
    10809199
  • 财政年份:
    2023
  • 资助金额:
    $ 216.95万
  • 项目类别:
Exercise and TLR: Mechanisms underlying resilience to chronic stress
运动和 TLR:慢性压力恢复能力的机制
  • 批准号:
    10730416
  • 财政年份:
    2023
  • 资助金额:
    $ 216.95万
  • 项目类别:
Neuroimmune mechanisms of adult chronic ethanol consumption
成人慢性乙醇消耗的神经免疫机制
  • 批准号:
    10727281
  • 财政年份:
    2023
  • 资助金额:
    $ 216.95万
  • 项目类别:
Elucidating the neuroimmune mechanisms underlying pain and inflammation in autoimmune arthritis
阐明自身免疫性关节炎疼痛和炎症的神经免疫机制
  • 批准号:
    10784407
  • 财政年份:
    2023
  • 资助金额:
    $ 216.95万
  • 项目类别:
Molecular mechanisms underlying T cell resistance to PD-1 signaling
T 细胞抵抗 PD-1 信号传导的分子机制
  • 批准号:
    10714460
  • 财政年份:
    2023
  • 资助金额:
    $ 216.95万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了